Results for tag: "Spinraza"

Spinraza is a drug used to treat spinal muscular atrophy (SMA), a rare genetic disorder that affects the muscles and nerves. It is the first and only approved treatment for SMA, and is administered via intrathecal injection. Spinraza works by increasing the production of a protein called SMN, which is essential for the development and maintenance of motor neurons. It is approved for use in both adults and children, and has been shown to improve motor function and quality of life in those with SMA. The Spinraza market is a rapidly growing segment of the musculoskeletal disorders drugs market. It is estimated that the global SMA market will reach $3.5 billion by 2027, driven by the increasing prevalence of SMA and the availability of Spinraza. The market is expected to be driven by the increasing awareness of SMA, the availability of new treatments, and the increasing number of clinical trials. Some of the key players in the Spinraza market include Biogen, Ionis Pharmaceuticals, Novartis, Roche, and Pfizer. Show Less Read more